Olympus Corp (ADR) (NASDAQOTH:OCPNY)

CAPS Rating: No stars

Results 1 - 3 of 3

Recs

0
Member Avatar dnelyo (< 20) Submitted: 11/25/2011 11:25:46 AM : Underperform Start Price: $13.56 OCPNY Score: -86.32

delisting possible

Recs

0
Member Avatar catfishalex (95.84) Submitted: 5/6/2010 7:10:33 PM : Outperform Start Price: $30.30 OCPNY Score: -52.21

hate the crappy digital cameras, love the simoidoscopes. recent studies have shown that flexible sigmoidoscopy can greatly reduce colon cancer death rates and is an easier procedure to do than a colonoscopy and will be used to see if a colonoscopy is necessary. I expect sigmoidoscope usage to skyrocket.

Recs

0
Member Avatar didIpickthat (< 20) Submitted: 1/30/2008 9:05:59 PM : Outperform Start Price: $33.45 OCPNY Score: -50.02

The next wave of advanced endoscopic surgery is currently being developed and in minimally invasive surgery. Olympus will be buying out ACMI to get a hold of 2 patents that are needed for this break through surgery. Currently, studies are underway in Asia and Europe with promising results. Stayed tuned for the next big break-through in surgical procedures. It will mean big gains for this company.

Results 1 - 3 of 3

Featured Broker Partners


Advertisement